Verano Holdings (VRNO) Depreciation & Amortization (CF) (2021 - 2026)
Verano Holdings (VRNO) reported Depreciation & Amortization (CF) of $29.2 million for Q1 2026, down 8.19% year-over-year from $31.8 million in Q1 2025, and little changed quarter-over-quarter from $29.3 million in Q4 2025.
Verano Holdings (VRNO) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $29.2 million in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $29.2 million, down 8.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $121.6 million (down 10.56% YoY), and the FY2025 annual result was $124.2 million, down 11.1% from the prior year.
- Depreciation & Amortization (CF) steadied at $29.2 million in Q1 2026 per VRNO's latest filing, from $29.3 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $36.9 million in Q3 2024 and troughed at $29.2 million in Q1 2026.
- A 5-year average of $33.9 million and a median of $35.2 million in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 46.15% in 2022, then slipped 14.39% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $35.2 million in 2022, then gained by 1.19% to $35.6 million in 2023, then fell by 11.41% to $31.5 million in 2024, then dropped by 6.97% to $29.3 million in 2025, then fell by 0.44% to $29.2 million in 2026.
- Business Quant data shows VRNO's Depreciation & Amortization (CF) at $29.2 million in Q1 2026, $29.3 million in Q4 2025, and $31.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Verano Holdings | - | - | 98.98 Mn | 29.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.19 Mn |
| Mar 31, 2026 | 29.19 Mn |
| Dec 31, 2025 | 29.32 Mn |
| Dec 31, 2025 | 29.32 Mn |
| Sep 30, 2025 | 31.56 Mn |
| Sep 30, 2025 | 31.56 Mn |
| Jun 30, 2025 | 31.49 Mn |
| Jun 30, 2025 | 31.49 Mn |
| Mar 31, 2025 | 31.79 Mn |
| Mar 31, 2025 | 31.79 Mn |
| Dec 31, 2024 | 31.51 Mn |
| Dec 31, 2024 | 31.51 Mn |
| Sep 30, 2024 | 36.87 Mn |
| Sep 30, 2024 | 36.87 Mn |
| Jun 30, 2024 | 35.73 Mn |
| Jun 30, 2024 | 35.73 Mn |
| Mar 31, 2024 | 35.55 Mn |
| Mar 31, 2024 | 35.55 Mn |
| Dec 31, 2023 | 35.57 Mn |
| Dec 31, 2023 | 35.57 Mn |